Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen
Authors:
- Gerassimos A. PangalisGPGerassimos A. Pangalis
- Theodoros P. VassilakopoulosTheodoros P. Vassilakopoulos
- 6 December 2010
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (3) , 387-393
Abstract
The optimal treatment approach for patients with mantle cell lymphoma (MCL) is not well defined. Intensive therapeutic regimens result in high response rates and prolonged progression-free survival but at the expense of significant toxicity. We report here our results of the administration of rituximab plus chlorambucil (R-Chl) as first line treatment in patients with MCL. Twenty consecutively diagnosed patients were treated with this combination in which an induction and a maintenance arm were included. During induction, rituximab was administered at a dose of 375 mg/m2 on day 1, while chlorambucil was given afterward at a dose of 10 mg/day for 10 consecutive days for eight cycles and then as a single agent for an additional four cycles. Maintenance consisted of rituximab administration every 2 months for 1 year. Most patients had indolent disease features such as a low mantle-cell international prognostic index (MIPI) score. The overall response rate was 95% (90% CR, 5% PR). Among patients in CR, 78% presented a molecular remission. The 3-year progression-free survival was 89%. There were no serious side effects. These results show that the R-Chl combination could be an effective therapeutic option as first line treatment in MCL, especially for patients with indolent disease characteristics.Keywords
This publication has 32 references indexed in Scilit:
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyBlood, 2010
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008
- Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphomaLeukemia & Lymphoma, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Blood, 2006
- Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphomaBritish Journal of Haematology, 2005
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood, 2005
- Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)Journal of Clinical Oncology, 2005
- Topoisomerase IIα as a prognostic factor in mantle cell lymphomaLeukemia, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958